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Abstract
Purpose The independent predictive information from
progesterone receptor (PgR) positivity for breast cancer
treated with tamoxifen has been questioned after an over-
view by the Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG). However, the studies in the overview
were to a large content performed before modern PgR
immunohistochemistry (IHC) was developed. We therefore
investigated the predictive value of PgR determined with
IHC in estrogen receptor (ER)-positive tumors from
patients participating in the Stockholm trial of adjuvant
tamoxifen therapy.
Methods The Stockholm Breast Cancer Study Group
conducted a randomized trial during 1976 through 1990
comparing adjuvant tamoxifen versus control. The patients
were stratified according to tumor size and lymph node
status in high-risk and low-risk groups. In this study, we
evaluated 618 patients with ER-positive ‘‘low-risk’’ breast
cancer (size B 30 mm, lymph node-negative) for whom
PgR was determined by IHC at one pathology laboratory.
The median time of follow-up was 21 years.
Results Patients with ER-positive tumors that were also
PgR-positive by IHC did benefit from tamoxifen, while we
could not show any long-term benefit for those with tumors
positive for ER only (recurrence rate ratio 0.43, 95 % CI
0.29–0.62 and 0.87, 95 % CI 0.52–1.46, respectively). We
further investigated the influence of different levels of PgR
positivity on recurrence risk. The results show that at all
receptor levels with C10 % stained PgR-positive cells, the
patients did benefit from tamoxifen. There was no clear
linear trend in benefit with increasing proportion of stained
cells.
Conclusions PgR positivity determined by IHC is a marker
indicating long-term benefit from adjuvant tamoxifen in
patients with ER-positive tumors.
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Progesterone receptor
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Introduction
The estrogen and progesterone receptors are predictors of
the benefit of endocrine therapy in both primary and
metastatic breast cancers [1–4]. Before approximately
1995, cytosol ER and PgR were measured by ligand
binding or immunochemical methods measuring receptor
content in tumor tissue consisting of both cancer cells and
stromal cells. With immunohistochemistry (IHC), which
does not require fresh material, ER and PgR are assessed in
cancer cells only. Comparing different levels of hormone
receptors in relation to the efficacy of adjuvant tamoxifen,
the EBCTCG was unable to find a predictive value of PgR
in patients known to have ER-positive disease [1]. This is
in contrast to findings with adjuvant tamoxifen therapy of
premenopausal patients demonstrating PgR determined by
IHC to be a stronger predictor of tamoxifen benefit than ER
[3]. The aim of this study was to investigate the predictive
value of PgR determined by IHC in ER-positive breast
cancer. A second aim was to investigate if the effect varies
over time and/or with increased levels of PgR positivity.
For this, we used tumors from a well-defined randomized
clinical adjuvant trial with long-term follow-up. We further
discuss whether the method of assessing the hormone
receptors may affect trial conclusions.
Methods
Study design
Patients with operable invasive breast cancer were entered
previously in detail described study of adjuvant tamoxifen
therapy conducted by the Stockholm Breast Cancer Study
Group [4]. Postmenopausal women younger than 70 years
were randomly given tamoxifen postoperatively at a dose
of 40 mg per day compared with no adjuvant endocrine
therapy. During November 1976 through June 1990, 2738
patients entered the trial. Among them, 1780 patients
(65 %) with no lymph node metastases and a tumor
diameter of 30 mm or less (established by histological
examination) were classified as ‘‘low risk’’ and did not
receive cytotoxic chemotherapy. In this group, 432 patients
were treated with breast conserving surgery including
axillary dissection plus radiation to the breast (50 Gy/
5 weeks). The remaining 1348 patients had a modified
radical mastectomy and no radiotherapy. From the low-risk
patients, we found paraffin blocks from 912 for construc-
tion of microtissue arrays (TMAs). The trial included
patients irrespectively of hormone receptor content, but
prospectively collected data on ER and PgR status were
available and archived tumor tissue had sufficiently high
quality for IHC analysis in 795 cases. These patients had
similar age distribution, tumors of similar size, and pro-
portion of ER-positive tumors as the entire group of 1780
patients with low-risk tumors. The proportion of patients
randomized to tamoxifen therapy was 52 % as compared to
50 % in the entire group. Among the tumors analyzed for
PgR by IHC, 591 were ER-positive as determined by IHC,
while 27 tumors with missing data on ER by IHC were ER-
positive according to cytosol analysis, resulting in 618 ER-
positive tumors (Fig. 1).
Follow-up strategies
Yearly clinical visits included a physical examination and a
mammogram. Chest X-ray, blood sampling, bone scans,
etc., were performed if clinical symptoms and signs indi-
cated a probable relapse. Disease recurrence was confirmed
when possible by biopsy. Recurrence was dated from the
first evidence of relapse based on physical, histological, or
imaging data. After recurrence, treatment was decided
individually. The current results were based on follow-up
until December 31, 2014.
”Low-risk” postmenopausal patients 
≤70 years old
1780 patients
TMA Paraffin blocks available
912 patients










Fig. 1 Summary of trial design
314 Breast Cancer Res Treat (2016) 160:313–322
123
Hormone receptor determination
Before 1988, ER and PgR were determined using isoelec-
tric focusing on polyacrylamide gel as previously described
[5]. After 1988, an enzyme immunoassay was used. For
ER, studies have shown that results with these techniques
correlate well with those obtained using methods based on
dextran-coated charcoal and IHC [2]. The cytosol receptor
values were normalized to DNA content, and a receptor
content of C0.05 fmol/lg DNA was classified as positive.
The IHC staining was performed using the Ventana HX
automatic system BenchMark (Ventana Medical System,
SA IllKirch, Cedex, France). Primary monoclonal anti-
bodies were the CONFIRMTM mouse anti-ER antibody
(clone 6F11) and the CONFIRMTM mouse anti-PR anti-
body (clone 16) from Ventana Medical Systems. Antigen
retrieval and staining procedure were performed according
to the instruction by the Ventana manufacture. Positive
controls were run with each batch. Only the invasive part
of the carcinoma was assessed, and for each case, all three
cores of the TMA were reviewed. The receptor levels
presented are based on an average of the three cores of the
TMA. The proportion of stained nuclei was recorded as 0,
1–9 %, 10–24 %, 25–49 %, 50–74 %, 75–89 %,
and C90 %. The scoring was done by two pathologists
(B.L; L.S.).
Statistical methods
To compare the association between PgR expression and
clinical parameters, the Pearson Chi squared test (cate-
gorical variables) and the Student’s t test (continuous
variables) were applied. Time for follow-up was defined as
the time from randomization until the first event, death, or
last observation. For cumulative recurrence risk (CRR) and
cumulative distant recurrence risk (CDRR), the last
observation was December 31, 2014 and for cumulative
breast cancer-specific mortality (CBCSM) December 31,
2012. CRR, CDR,R and CBCSM were estimated by the
Kaplan–Meier method. The events in calculations of CRR
were loco-regional recurrence, distant recurrence, and
death due to breast cancer. In the calculations of CDRR,
the events were distant recurrence and death due to breast
cancer, and in CBCSM death due to breast cancer. In all
these analyses, we censored for death due to other causes.
Hazard ratios (HR) and 95 % confidence intervals (CIs)
were estimated using the Cox’s proportional hazards
model. A p value of\0.05 was considered to be statisti-
cally significant. The proportional hazards assumption was
checked by log-minus-log plots of the hazard functions. In
analyses where the proportional hazards assumptions was
violated, Cox regression divided by different time periods
was applied. We also examined crude cumulative
incidence rates [6]. This is failure probabilities for a par-
ticular type of event, in the presence of other events, which
may impede the event of interest to occur. Death due to
other causes than breast cancer was considered as a com-
peting event. In order to understand the pattern of the
treatment effect of tamoxifen for different PgR values, a
subpopulation treatment effect pattern plot (STEPP) anal-
ysis was performed [7]. For this purpose, the program stepp
tail implemented in Stata was used [8]. The parameter
g was set to 7, generating 13 overlapping subgroups (six for
decreasing PgR values, one for all patients, and six for
increasing PgR values). The STEPP figures show the
estimated effect of tamoxifen in each of these subgroups
from a graphical view.
The statistical analyses were performed using STATA/
SE 13.1. Our study was reported according to the Report-
ing Recommendations for Tumor Marker Prognostic
Studies (REMARK) criteria [9].
Results
The PgR expression was analyzed with IHC for 795
tumors. Almost half of them (375 tumors) were considered
as PgR negative with\10 % stained cells. Furthermore,
the percentage of PgR-positive tumor cells was as follows:
10–49 % in 127 tumors, 50–74 % in 119 tumors,
and C75 % in 174 tumors. Table 1 shows other tumor
characteristics in relation to PgR status. It is notable that
nearly all PgR-positive tumors were also ER-positive and
seldom HER2-positive.
Effect of tamoxifen in subgroups
Results from the present trial have previously shown a
significantly reduced recurrence rate among patients with
ER-positive tumors randomized to tamoxifen therapy ver-
sus control [HR = 0.53 (0.37–0.74), p\ 0.001] [2].
Patients with ER?/PgR? tumors receiving tamoxifen
had a reduced recurrence risk compared with those who
were not treated with tamoxifen (HR = 0.43, 95 % CI
0.29–0.62, p\ 0.001) (Table 2). For patients with ER?/
PgR- tumors, the effect of the treatment was time-de-
pendent. The first 5 years after diagnosis the tamoxifen-
treated patients had a reduced recurrence risk (HR = 0.39,
95 % CI 0.15–1.00, p = 0.05), whereas it increased
thereafter (HR = 1.34, 95 % CI 0.69–2.60, p = 0.39)
(Table 3). P for interaction between PgR status and treat-
ment was 0.55 the first 5 years and 0.03 after this time
period. Seen over the whole time period, the relative risk
ratio for tamoxifen treatment versus the control group
when comparing PgR? and PgR- tumors was 0.49 (95 %
CI 0.25–0.92, p = 0.03). During the first 5 years, it was
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0.70 (95 % CI 0.22–2.22, p = 0.55) and during the latter
time period 0.41 (95 % CI 0.18–0.92, p = 0.03).
The risk reduction for the tamoxifen-treated patients vs.
the control group was similar considering breast cancer-
specific mortality and distant recurrence risk (Table 2).
Hazard ratio for breast cancer-specific mortality was 0.44
(95 % CI 0.27–0.71, p = 0.001) for ER?/PgR? patients
and 0.65 (95 % CI 0.35–1.21, p = 0.17) for ER?/PgR-
patients. The corresponding HR for distant recurrence risk
was 0.45 (95 % CI 0.29–0.70, p\ 0.001) for ER ?/
PgR ? patients and 0.75 (95 % CI 0.42–1.34, p = 0.33)
for ER?/PgR- patients.
The cumulative incidence functions adjusting for com-
peting risks showed lower recurrence risks for both
tamoxifen-treated and untreated patients compared with the
risks computed with the Kaplan–Meier method (data not
shown). However, the relative risks between the treatment
groups were similar, irrespective of the statistical method
used.
The results show that tamoxifen therapy resulted in a
marked benefit for patients with tumors positive for both
receptors, while we could not show any long-term benefit
from tamoxifen for those with tumors positive for ER only
(Fig. 2; Table 3).
Effect of tamoxifen at different levels of PgR
positivity
We further investigated the influence of different levels of
PgR positivity on the recurrence risk. The results in Fig. 3
and Table 4 show that at all receptor levels with C10 %
stained cells, there was a benefit from tamoxifen. The
hazard ratios between tamoxifen vs. no tamoxifen for the
groups of 10–49 %, 50–74 %, and C75 % PgR stained
cells were 0.30 (95 % CI 0.16–0.58, p\ 0.001), 0.38
(95 % CI 0.18–0.80, p = 0.011), and 0.59 (95 % CI
0.32–1.08, p = 0.09), respectively. We could not show any
benefit from tamoxifen among patients with 1–9 % PgR-
positive tumor cells (HR = 1.11, 95 % CI 0.38–3.24,
p = 0.84). To further investigate tamoxifen treatment
effect differences across the continuum of PgR levels, we
performed STEPP analyses (Fig. 4). The STEPP curves
show the effect of tamoxifen on the recurrence risk during
the first 5 years after diagnosis (Fig. 4a), after the first
Table 1 Characteristics for patients with PgR expression determined
by IHC
PgR n (%) Total p value
\10 % C10 %










\20 225 (61) 307 (74) 532 (68) \0.001
C20 144 (39) 107 (26) 251 (32)
Unknown 6 6 12
ER status
Negative 161 (43) 9 (2) 170 (22) \0.001
Positive 211 (57) 407 (98) 618 (78)
Unknown 3 4 7
PgR status (cytosol)
Negative 205 (78) 92 (30) 297 (52) \0.001
Positive 57 (22) 214 (70) 271 (48)
Unknown 113 114 227
HER2a
Negative 280 (80) 388 (97) 668 (89) \0.001
Positive 72 (20) 13 (3) 85 (11)
Unknown 23 19 42
a HER2 was assessed with immunohistochemistry as previously
described [23]
Table 2 Outcome for patients with ER positive tumors divided by PgR (IHC) status
Tam vs. control PgR (IHC) Number of patients/events HR (95 % CI) p value P for interaction
TAM Control
Recurrence rate All 329/70 289/102 0.54 (0.40–0.74) \0.001 0.03
C10 % 225/43 182/72 0.43 (0.29–0.62) \0.001
\10 % 104/27 107/30 0.87 (0.52–1.46) 0.59
Distant recurrence rate All 329/51 289/79 0.54 (0.38–0.76) 0.001 0.17
C10 % 225/31 182/53 0.45 (0.29–0.70) \0.001
\10 % 104/20 107/26 0.75 (0.42–1.34) 0.33
Breast cancer specific mortality rate All 329/43 289/72 0.51 (0.35–0.74) \0.001 0.33
C10 % 225/26 182/47 0.44 (0.27–0.71) 0.001
\10 % 104/17 107/25 0.65 (0.35–1.21) 0.17
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5 years (Fig. 4b), and over the whole time period (Fig. 4c),
for overlapping subgroups with different mean PgR IHC
values. The STEPP curves indicated some effect of
tamoxifen even in patients with ER?/PgR- tumors the
first 5 years after diagnosis. This is in line with the data in
Fig. 2 indicating a minor benefit from tamoxifen also for
Table 3 Outcome for patients with ER positive tumors divided by PgR (IHC) status and different time periods
Tam vs. control PgR
(IHC)
0–5 years Beyond 5 years
Number of
patients/events
HR (95 % CI) p value Number of
patients/events
HR (95 % CI) p value
TAM Control TAM Control
Recurrence rate All 329/18 289/48 0.31 (0.18–0.53) \0.001 294/52 228/54 0.74 (0.51–1.09) 0.13
C10 % 225/12 182/33 0.27 (0.14–0.53) \0.001 199/31 143/39 0.55 (0.34–0.88) 0.012
\10 % 104/6 107/15 0.39 (0.15–1.00) 0.051 95/21 85/15 1.34 (0.69–2.60) 0.39
Breast cancer specific mortality
rate
All 329/7 289/14 0.43 (0.18–1.08) 0.072 305/36 265/58 0.53 (0.35–0.80) 0.002
C10 % 225/3 182/9 0.27 (0.07–0.99) 0.049 208/23 169/38 0.48 (0.29–0.81) 0.006
\10 % 104/4 107/5 0.81 (0.22–3.00) 0.75 97/13 96/20 0.61 (0.31–1.24) 0.17
Fig. 2 PgR expression determined with IHC. Cumulative recurrence
risk for patients with ER?/PgR? tumors, HR = 0.43 (95 % CI
0.29–0.62), p\ 0.001 (a) and ER?/PgR- tumors, HR = 0.87 (95 %
CI 0.52–1.46), p = 0.59 (b). Cumulative breast cancer-specific
mortality for patients with ER?/PgR? tumors, HR = 0.44 (95 %
CI 0.27–0.71), p = 0.001 (c) and ER?/PgR- tumors, HR = 0.65
(95 % CI 0.35–1.21), p = 0.17 (d)
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patients with ER-positive tumors with no or less than 10 %
PgR- positive cells.
Our data demonstrating significant more benefit from
tamoxifen in patients with tumors positive for both ER and
PgR as compared with patients with tumors positive for ER
alone, in part contrast to the data in the EBCTCG review.
However, as presented in the overview, only a minor
proportion of the PgR values were obtained with IHC. In
the present cohort of 618 patients with ER-positive tumors,
cytosol PgR information was available in 449 cases. In 254
tumors (57 %), the cytosol assay was positive. The data in
Fig. 5 and Supplementary Table 1 illustrate that, in
Fig. 3 Influence of increasing proportion of PgR-positive tumor cells
on cumulative recurrence risk among patients with ER-positive
tumors. PgR 1–9 %, HR = 1.11 (95 % CI 0.38–3.24), p = 0.84 (a),
PgR 10–49 %, HR = 0.30 (95 % CI 0.16–0.58), p\ 0.001 (b), PgR
50–74 %, HR = 0.38 (95 % CI 0.18–0.80), p = 0.011 (c),
PgR C 75 %, HR = 0.59 (95 % CI 0.32–1.08), p = 0.086 (d)
Table 4 Outcome for patients with ER positive tumors divided by different levels of PgR (IHC) expression and different time periods
Tam vs. control PgR (IHC) (%) 0–5 years Beyond 5 years
Number of patients/
events
HR (95 % CI) p value Number of patients/
events
HR (95 % CI) p value
TAM Control TAM Control
Recurrence rate 0 79/4 82/13 0.29 (0.09–0.89) 0.031 73/15 64/11 1.34 (0.62–2.93) 0.46
1–9 25/2 25/2 1.07 (0.15–7.56) 0.95 22/6 21/4 1.14 (0.32–4.05) 0.85
10–49 70/8 50/12 0.44 (0.18–1.07) 0.069 59/6 37/15 0.21 (0.08–0.54) 0.001
50–74 63/2 52/10 0.15 (0.03–0.69) 0.015 55/9 40/10 0.59 (0.24–1.46) 0.26
C75 92/2 80/11 0.15 (0.03–0.67) 0.013 85/16 66/14 0.93 (0.45–1.91) 0.85
318 Breast Cancer Res Treat (2016) 160:313–322
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agreement with the EBCTCG review, PgR positivity
determined with our cytosol assay did not predict tamox-
ifen benefit more efficiently than ER positivity alone.
Discussion
We have shown that IHC determined PgR positivity in at
least 10 % of the tumor cells predicts reduced recurrence
risk after adjuvant tamoxifen therapy for patients with ER-
positive tumors. For patients with 1–9 % PgR-positive
tumor cells, we observed a similar recurrence rate in both
treatment arms. However, this group included only 50
patients with 14 events. We are therefore unable to exclude
that this group of patients shows some benefit from
tamoxifen.
Our data in part contrast to those in the EBCTCG
overview [1]. This discrepancy may be explained by the
different techniques used to demonstrate PgR positivity.
In most trials in the EBCTCG overview, different forms
of cytosol-based assays were used. It is stated that 21 % of
the ER-negative cancers were PgR-positive, indicating that
the PgR technique used resulted in many false positive PgR
classifications. With modern IHC and gene expression
assays, it has been clearly demonstrated that PgR positivity
or PgR gene expression is a rare event demonstrated in
1–4 % of ER-negative tumors [10]. Another aspect is the
possible time dependence of the ability of PgR to predict
the efficacy of adjuvant tamoxifen. The follow-up period in
the present study was long and the predictive value for PgR
was most evident beyond 5 years of follow-up. Further-
more, the patients in the present study did not receive
Fig. 4 Subpopulation treatment effect pattern plots (STEPP), show-
ing the effect of tamoxifen vs. no tamoxifen on the recurrence risk
during the first 5 years after diagnosis (a), more than 5 years after
diagnosis (b) and over the whole time period (c) in relation to PgR
values measured with IHC. HR (solid black line) with the
corresponding 95 % confidence interval (dashed gray lines) is plotted
against the mean PgR. The dotted black line shows the HR for
tamoxifen vs. control for all PgR values in the selected time period.
The analysis was confined to patients with ER-positive tumors
Breast Cancer Res Treat (2016) 160:313–322 319
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adjuvant chemotherapy. Potential differences in tamoxifen
benefit in relation to PgR levels could possibly be masked
by the effect of chemotherapy, in particular in cohorts
where the use of chemotherapy is not balanced between
patients with ER?/PgR? and ER?/PgR- tumors.
Our present results may be compared to those obtained
with the randomized trial comparing 2 and 5 years of
adjuvant tamoxifen therapy, which demonstrated that PgR
positivity was a strong predictor of the benefit of 5 years of
tamoxifen in patients with ER-positive tumors. The results
were probably influenced by the fact that a major propor-
tion of the receptor data were obtained with immunoassays,
and the cytosol assays were concentrated to two laborato-
ries participating in a quality control program [11]. In a
study by Bardou et al. [12], clinical outcomes of patients in
two large databases were analyzed as a function of steroid
receptor status. Receptor assays were concentrated to two
laboratories and in agreement with our data they concluded
that when accurately measured, PgR status is an indepen-
dent predictive factor for benefit from adjuvant endocrine
therapy. The significance of PgR has also been demon-
strated in metastatic ER? breast cancer, where increased
levels of PgR improved the response rate to tamoxifen [13].
PgR positivity determined by IHC was previously shown to
be a strong predictor of the benefit of adjuvant tamoxifen in
premenopausal patients [3, 14]; this finding is now exten-
ded to postmenopausal patients.
We and others have demonstrated that ER measured by
ligand binding and IHC yield similar proportions of ER-
positive tumors, and both types of assays may be used to
predict response to tamoxifen therapy [2]. In contrast, even
the most experienced laboratories have reported poor cor-
relation between PgR data obtained with IHC and ligand
binding assays. Elledge et al. found that 38 % of the
Fig. 5 PgR expression determined with cytosol assays. Cumulative
recurrence risk for patients with ER?/PgR? tumors, HR = 0.45
(95 % CI 0.28–0.72), p = 0.001 (a) and ER?/PgR- tumors,
HR = 0.48 (95 % CI 0.27–0.87), p = 0.015 (b). Cumulative breast
cancer-specific mortality for patients with ER?/PgR? tumors,
HR = 0.49 (95 % CI 0.27–0.87), p = 0.015 (c) and ER?/PgR-
tumors, HR = 0.35 (95 % CI 0.16–0.75), p = 0.007 (d)
320 Breast Cancer Res Treat (2016) 160:313–322
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tumors, which were PgR negative with ligand binding,
were PgR-positive with IHC [15]. A similar number of
30 % was found in the present study (Table 1).
Patients with ER- and PgR-positive tumors have their
recurrence rate approximately halved by 2 years of adjuvant
tamoxifen therapy. Thus, many experience recurrence in
spite of having this tumor pattern. We and others have shown
that alterations of the PI3K/Akt/mTOR- growth signaling
pathway correlate to resistance to endocrine therapy, partly
through regulation of ER activity. This mechanism of
resistance seems to operate in ER-positive tumors also
strongly positive for PgR. This is in line with our previous
observation that in tamoxifen-treated patients, low levels of
p-mTOR-2448 combined with ER and PgR positivity pre-
dicts a prolonged recurrence-free survival [16].
Our data may be compared with those of Dowsett and
colleagues using IHC to analyze tumors from the NATO
and CRC trials [17]. In contrast to our data, PgR positivity
did not predict further tamoxifen benefit for patients with
ER-positive tumors. We are unable to explain this differ-
ence but a different scoring system yielding a higher pro-
portion of PgR-positive cells may have contributed to the
difference. Also, Dowsett et al. found that 13 % of the ER-
negative tumors were PgR-positive, and this subgroup
tended to benefit from tamoxifen therapy.
PgR is an ER-regulated protein, and the presence of PgR
in the cancer cells has long been considered as a result of
activated ER. Therefore, our finding that patients with a
tumor containing both ER and PgR did benefit from
tamoxifen therapy seems reasonable. However, according
to Cui et al. [18], the absence of PgR may not only reflect a
lack of ER activity, but rather a hyperactive cross talk
between ER and growth factor signaling pathways that
downregulate PgR even as they activate other ER func-
tions. Therefore, the authors suggest that estrogen deple-
tion therapy, such as aromatase inhibitors, may be more
suited for ER?/PgR- tumors. Other studies have not
shown any particular advantage of aromatase inhibitors
over tamoxifen for ER?/PgR- tumors compared with
other subgroups [19–21]. We suggest that IHC determined
tumor content of both ER and PgR should be taken into
consideration when breast cancer patients receive postop-
erative advice. Patients with tumors positive for both
receptors may be informed that tamoxifen therapy often
provides long-term protection against disease recurrence.
For patients with tumors positive for ER only, cytotoxic
therapy may be discussed as additional treatment, which is
also in line with the St Gallen consensus [22].
Acknowledgments We thank Ulla Johansson for care and update of
the database and Birgitta Holmlund for technical assistance.
Funding Financial support was obtained from the Swedish Cancer
Society (Sta˚l), The Swedish Breast Cancer Association
(Nordenskjo¨ld), The Cancer Research Foundations of Radiumhemmet
(Fornander), Cancer Society in Stockholm (Fornander), King Gustav
V Jubilee Clinical Research Foundation (Fornander), County Council
of O¨stergo¨tland (Fohlin), and Onkologiska Klinikernas i Linko¨ping
Forskningsfond (Fohlin). The funders had no role in the study design,
data collection, analysis, interpretation of the data, or writing of the
report.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the local ethical committee at the Karolinska University Hospital (KI
97-451 with amendment 030201) and with the 1964 Helsinki decla-
ration and its later amendments or comparable ethical standards.
Informed consent According to the ethical approval informed con-
sent from the patients was not required.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Davies C G, Godwin J, Gray R, Clarke M, Cutter D, Darby S,
McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J,
Peto R, Early Breast Cancer Trialists’Collaborative (2011) Rel-
evance of breast cancer hormone receptors and other factors to
the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
randomised trials. Lancet 378(9793):771–784. doi:10.1016/
S0140-6736(11)60993-8
2. Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T, Stal O,
Skoog L, Bergh J, Nordenskjold B (2011) Immunohistochemistry
compared to cytosol assays for determination of estrogen receptor
and prediction of the long-term effect of adjuvant tamoxifen.
Breast Cancer Res Treat 126(2):421–430. doi:10.1007/s10549-
010-1202-7
3. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G,
Jirstrom K (2006) High progesterone receptor expression corre-
lates to the effect of adjuvant tamoxifen in premenopausal breast
cancer patients. Clin Cancer Res 12(15):4614–4618. doi:10.1158/
1078-0432.CCR-06-0248
4. Rutqvist LE, Johansson H, Stockholm Breast Cancer Study G
(2007) Long-term follow-up of the randomized Stockholm trial
on adjuvant tamoxifen among postmenopausal patients with early
stage breast cancer. Acta Oncol 46(2):133–145. doi:10.1080/
02841860601034834
5. Wrange O, Nordenskjold B, Gustafsson JA (1978) Cytosol
estradiol receptor in human mammary carcinoma: an assay based
on isoelectric focusing in polyacrylamide gel. Anal Biochem
85(2):461–475
6. Marubini E, Valsecchi M (1995) Competing risks. In: V B (ed)
Statistics in practice: Analysing survival data from clinical trials
and observational studies. John Wiley and Sons, Chichester,
pp 331–363
Breast Cancer Res Treat (2016) 160:313–322 321
123
7. Bonetti M, Gelber RD (2000) A graphical method to assess
treatment-covariate interactions using the Cox model on subsets
of the data. Stat Med 19(19):2595–2609
8. Royston P, Sauerbrei W (2004) A new approach to modelling
interactions between treatment and continuous covariates in
clinical trials by using fractional polynomials. Stat Med
23(16):2509–2525. doi:10.1002/sim.1815
9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M,
Clark GM (2006) REporting recommendations for tumor MAR-
Ker prognostic studies (REMARK). Breast Cancer Res Treat
100(2):229–235. doi:10.1007/s10549-006-9242-8
10. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B,
Tamimi RM, Beck AH (2013) Estrogen receptor negative/pro-
gesterone receptor positive breast cancer is not a reproducible
subtype. Breast Cancer Res 15(4):R68. doi:10.1186/bcr3462
11. Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC,
Malmstrom P, Nordenskjold B, Ryden S (2000) Results of two or
five years of adjuvant tamoxifen correlated to steroid receptor and
S-phase levels. South Sweden Breast Cancer Group, and South-
East Sweden Breast Cancer Group. Breast Cancer Res Treat
59(1):69–76
12. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM
(2003) Progesterone receptor status significantly improves out-
come prediction over estrogen receptor status alone for adjuvant
endocrine therapy in two large breast cancer databases. J Clin
Oncol 21(10):1973–1979. doi:10.1200/JCO.2003.09.099
13. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh
RP, Carter RD, Rivkin SE, Borst JR, Belt RJ et al (1992) Prog-
nostic significance of progesterone receptor levels in estrogen
receptor-positive patients with metastatic breast cancer treated
with tamoxifen: results of a prospective Southwest Oncology
Group study. J Clin Oncol 10(8):1284–1291
14. Ekholm M, Bendahl PO, Ferno M, Nordenskjold B, Stal O,
Ryden L (2016) Two years of adjuvant tamoxifen provides a
survival benefit compared with no systemic treatment in pre-
menopausal patients with primary breast cancer: long-term fol-
low-up ([25 years) of the Phase III SBII:2pre Trial. J Clin Oncol.
doi:10.1200/JCO.2015.65.6272
15. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J,
Ravdin P, Martino S, Osborne CK (2000) Estrogen receptor (ER)
and progesterone receptor (PgR), by ligand-binding assay com-
pared with ER, PgR and pS2, by immuno-histochemistry in
predicting response to tamoxifen in metastatic breast cancer: a
Southwest Oncology Group Study. Int J Cancer 89(2):111–117
16. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L,
Fornander T, Nordenskjold B, Stal O (2013) Activation of Akt,
mTOR, and the estrogen receptor as a signature to predict
tamoxifen treatment benefit. Breast Cancer Res Treat
137(2):397–406. doi:10.1007/s10549-012-2376-y
17. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A’Hern R,
Sainsbury R, Baum M (2006) Benefit from adjuvant tamoxifen
therapy in primary breast cancer patients according oestrogen
receptor, progesterone receptor, EGF receptor and HER2 status.
Ann Oncol 17(5):818–826. doi:10.1093/annonc/mdl016
18. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology
of progesterone receptor loss in breast cancer and its implications
for endocrine therapy. J Clin Oncol 23(30):7721–7735. doi:10.
1200/JCO.2005.09.004
19. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C,
Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M,
Gademann G, Kaufmann M, Wolfgang J, The ABCSG (2005)
Switching of postmenopausal women with endocrine-responsive
early breast cancer to anastrozole after 2 years’ adjuvant
tamoxifen: combined results of ABCSG trial 8 and ARNO 95
trial. Lancet 366(9484):455–462. doi:10.1016/S0140-6736(05)
67059-6
20. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman
RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I,
Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E,
Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning
PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A,
Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M,
Colajori E, Subar M, Ireland E, Bliss JM, Intergroup Exemestane
S (2007) Survival and safety of exemestane versus tamoxifen
after 2–3 years’ tamoxifen treatment (Intergroup Exemestane
Study): a randomised controlled trial. Lancet 369(9561):559–570.
doi:10.1016/S0140-6736(07)60200-1
21. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto
P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohls-
chlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M,
Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007)
Prognostic and predictive value of centrally reviewed expression
of estrogen and progesterone receptors in a randomized trial
comparing letrozole and tamoxifen adjuvant therapy for post-
menopausal early breast cancer: BIG 1-98. J Clin Oncol
25(25):3846–3852. doi:10.1200/JCO.2007.11.9453
22. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart
M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the
treatment of women with early breast cancer: highlights of the St
Gallen International Expert Consensus on the Primary Therapy of
Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.
1093/annonc/mdt303
23. Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L,
Nordenskjold B, Stal O (2009) Ratio of 17HSD1 to 17HSD2
protein expression predicts the outcome of tamoxifen treatment in
postmenopausal breast cancer patients. Clin Cancer Res
15(10):3610–3616. doi:10.1158/1078-0432.CCR-08-2599
322 Breast Cancer Res Treat (2016) 160:313–322
123
